Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 7/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823463 | 0.85 | SMN1; SMN2 (0.47) | SMN1; SMN2MAPK1SLC2A1KMT2AJAK1 | |
| SCHEMBL823454 | 0.85 | KDM4E (0.40) | SMN1; SMN2MAPK1TSHR | |
| SCHEMBL823469 | 0.83 | SLC2A1 (0.44) | SMN1; SMN2MAPK1SLC2A1 | |
| SCHEMBL823447 | 0.79 | KDM4E (0.56) | SMN1; SMN2KMT2ATSHR | |
| SCHEMBL823598 | 0.78 | KDM4E (0.41) | SMN1; SMN2CDK7 | |
| SCHEMBL823588 | 0.78 | KDM4E (0.35) | SMN1; SMN2TSHR | |
| SCHEMBL823577 | 0.75 | KDM4E (0.36) | SMN1; SMN2 | |
| SCHEMBL12894197 | 0.74 | L3MBTL1 (0.44) | SMN1; SMN2SLC2A1KMT2ATSHRHIF1A | |
| SCHEMBL823425 | 0.73 | SLC2A1 (0.46) | SMN1; SMN2SLC2A1KMT2AHIF1AEPAS1 | |
| SCHEMBL1221124 | 0.72 | SLC2A1 (0.44) | SMN1; SMN2MAPK1SLC2A1KMT2AJAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859563-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2014-10-14 | — | — | US | disclosed |
| US-8859563-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2014-10-14 | — | — | US | disclosed |
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-09-13 | — | — | US | disclosed |
| US-8207334-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-06-26 | — | — | US | disclosed |
| US-8143268-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-03-27 | — | — | US | disclosed |
| US-20110009366-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-01-13 | — | — | US | disclosed |
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | TPMT, TYMP, DPYD | SMN1; SMN2 1064/4885MAPK1 1853/4885SLC2A1 1705/4885 |
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | TPMT, TYMP, DPYD | SMN1; SMN2 1064/4885MAPK1 1853/4885SLC2A1 1705/4885 |
| US-20110009366-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | TPMT, TYMP, DPYD | SMN1; SMN2 1064/4885MAPK1 1853/4885SLC2A1 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.